Fulvestrant efficacy in artificial menopausal hormone receptor positive and HER 2 negative metastatic breast cancer patients under 50 years old.

Abstract

e13000Background: This study investigated the efficacy of fulvestrant in premenopausal patients with metastatic breast cancer who developed artificial menopause using a luteinizing hormone releasing hormone analogue. Methods: This retrospective study was conducted at the Istanbul Okmeydani Education and Research Hospital. Those patients receiving 3.6 mg of goserelin acetate for 28 days and 500 mg of intramuscular fulvestrant for 28 days were included. Results: A total of 37 patients were evaluated, with a median age of 39 years old (range 27–49) and a median follow-up time of 20 months (0–78). The estrogen receptor positivity was 83.8%, and the progesterone receptor positivity was 86.5%. Of these patients, 86.5% had invasive ductal carcinoma, 5.4% had invasive lobular carcinoma, and 8.1% had other histological types. Bone metastasis was found in 83.8% of the patients, lung metastasis in 21.6%, lymph node metastasis in 16.2%, liver metastasis in 13.5%, and brain metastasis in 5.4%. On average, the fulvestr...